Compare Hershey Co (HSY) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hershey Co vs State Street SPDR S&P Biotech ETF — how do they compare? Hershey Co trades at $171.69 (market cap $34.83B), while State Street SPDR S&P Biotech ETF trades at $152.24. The key difference: Hershey Co pays a 3.38% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Hershey Co nearer its low. Which is the better fit depends on your goals.
| HSY | XBI | |
|---|---|---|
Market Cap | $34.83B | — |
Sector | Consumer Staples | Broad Market / Factor |
52-Week High | $236.28 | $164.28 |
52-Week Low | $162.31 | $85.16 |
Enterprise Value | $39.63B | — |
Dividend Yield | 3.38% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hershey (HSY) trades at $170.63, down 0.46% on the day, with a bearish technical signal from moving averages. The company reported revenue of $11.69B for 2025 with a net income margin of 9.12%, though margins have compressed from prior years. Recent earnings have consistently beaten expectations, and the company announced a $1.45 dividend payable in June 2026. Analyst consensus is a 'Hold' with a price target of $207.82, indicating potential upside from current levels.
The outlook for HSY hinges on margin recovery as high cocoa costs cycle out. While valuation multiples appear elevated, consistent earnings beats and a solid dividend yield of approximately 3.4% provide support. Key risks include persistent volume weakness and competitive pressures. The stock presents a cautious opportunity for investors betting on a fundamental rebound in the second half of 2026.
XBI trades at $150.94, down 2.14% today, with technical indicators showing a bearish trend but oversold RSI suggesting potential near-term support. The ETF lacks traditional valuation metrics due to its structure, but recent news highlights strong biotech sector momentum, including a 17% monthly gain and robust M&A activity. Analyst coverage is limited to a single hold rating, reflecting cautious optimism amid sector volatility.
Outlook: Biotech sector tailwinds from M&A and AI-driven drug discovery offer upside, but high volatility and policy risks persist. Investors should weigh XBI's equal-weight exposure to small/mid-cap biotech against its elevated beta, with technical support near $149 critical for short-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
